Related Experiment Video
Updated: May 21, 2026
08:49
Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
Published on: August 2, 2024
Beta blocker therapy, decompensated heart failure, and inotropic interactions: current perspectives
1Department of Cardiovascular Medicine, Carmel Medical Center and Heart Failure Center, Lin Medical Center, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. barakz@bezeqint.net
The Israel Medical Association Journal : IMAJ
|June 9, 2012
Summary
Beta blockers are crucial for chronic heart failure (HF). This review highlights their safe use during decompensated HF hospitalizations, improving outcomes and reducing readmissions.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Beta blockers are standard for chronic heart failure (HF).
- Their use in decompensated HF (DHF) and during hospitalization remains debated.
- Evidence on efficacy and tolerability in DHF is growing.
Purpose of the Study:
- To review literature on beta blocker use in acute and chronic decompensated HF.
- To clarify the role of beta blockers during HF hospitalization.
- To discuss interactions between beta blockers and inotropes in DHF.
Main Methods:
- Literature review of studies on beta blocker treatment in decompensated heart failure.
- Analysis of clinical data regarding beta blocker withdrawal and initiation during hospitalization.
- Examination of interactions with positive inotropic agents.
Main Results:
- Chronic beta blocker withdrawal during hospitalization should be avoided if possible.
- Initiating beta blocker therapy upon achieving hemodynamic stability and euvolemia is recommended.
- This strategy may enhance post-discharge adherence and reduce rehospitalization and mortality.
Conclusions:
- Continuing or initiating beta blockers during decompensated HF hospitalization is beneficial.
- Optimizing beta blocker therapy in DHF can improve long-term patient outcomes.
- Understanding interactions with inotropes is key for managing complex DHF cases.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...